194 related articles for article (PubMed ID: 24975891)
41. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
[TBL] [Abstract][Full Text] [Related]
42. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
Dwyer JP; Sika M; Schulman G; Chang IJ; Anger M; Smith M; Kaplan M; Zeig S; Koury MJ; Blumenthal SS; Lewis JB;
Am J Kidney Dis; 2013 May; 61(5):759-66. PubMed ID: 23369827
[TBL] [Abstract][Full Text] [Related]
43. [Phosphate binders in chronic kidney disease: the positions of sevelamer].
Fomin VV; Shilov EM; Svistunov AA; Milovanov IuS
Ter Arkh; 2013; 85(6):96-9. PubMed ID: 23875200
[TBL] [Abstract][Full Text] [Related]
44. [The use of sevelamer in the treatment of resistant hyperphosphataemia in children with chronic renal disease].
Runowski D; Jachimiak B; Cieślak-Puchalska A; Pacanowska B; Zimoń T
Pol Merkur Lekarski; 2009 Apr; 26(154):318-21. PubMed ID: 19580197
[TBL] [Abstract][Full Text] [Related]
45. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan.
Koiwa F; Onoda N; Kato H; Tokumoto A; Okada T; Fukagawa M; Shigematsu T;
Ther Apher Dial; 2005 Aug; 9(4):340-6. PubMed ID: 16076379
[TBL] [Abstract][Full Text] [Related]
46. Sevelamer carbonate.
Barna MM; Kapoian T; O'Mara NB
Ann Pharmacother; 2010 Jan; 44(1):127-34. PubMed ID: 19955298
[TBL] [Abstract][Full Text] [Related]
47. Sevelamer worsens metabolic acidosis in hemodialysis patients.
De Santo NG; Frangiosa A; Anastasio P; Marino A; Correale G; Perna A; Di Stazio E; Stellato D; Santoro D; Di Meglio E; Iacono G; Ciacci C; Savica V; Cirillo M
J Nephrol; 2006; 19 Suppl 9():S108-14. PubMed ID: 16736432
[TBL] [Abstract][Full Text] [Related]
48. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.
Burke SK; Dillon MA; Hemken DE; Rezabek MS; Balwit JM
Adv Ren Replace Ther; 2003 Apr; 10(2):133-45. PubMed ID: 12879374
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
Mason MA; Shepler BM
Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
[TBL] [Abstract][Full Text] [Related]
50. Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients.
Cervelli MJ; Shaman A; Meade A; Carroll R; McDonald SP
Nephrology (Carlton); 2012 Jul; 17(5):458-65. PubMed ID: 22471559
[TBL] [Abstract][Full Text] [Related]
51. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients.
Yamada K; Fujimoto S; Tokura T; Fukudome K; Ochiai H; Komatsu H; Sato Y; Hara S; Eto T
Ren Fail; 2005; 27(4):361-5. PubMed ID: 16060120
[TBL] [Abstract][Full Text] [Related]
52. A randomized controlled trial of different serum phosphate ranges in subjects on hemodialysis.
Bhargava R; Kalra PA; Hann M; Brenchley P; Hurst H; Hutchison AJ
BMC Nephrol; 2019 Feb; 20(1):37. PubMed ID: 30717691
[TBL] [Abstract][Full Text] [Related]
53. Ten-year experience with sevelamer and calcium salts as phosphate binders.
Raggi P; Vukicevic S; Moysés RM; Wesseling K; Spiegel DM
Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S31-40. PubMed ID: 20089501
[TBL] [Abstract][Full Text] [Related]
54. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.
Spatz C; Roe K; Lehman E; Verma N
Nephron Clin Pract; 2013; 123(1-2):61-6. PubMed ID: 23774446
[TBL] [Abstract][Full Text] [Related]
55. Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients.
Katopodis KP; Andrikos EK; Gouva CD; Bairaktari ET; Nikolopoulos PM; Takouli LK; Tzallas CS; Elisaf MS; Pappas MV; Siamopoulos KC
Perit Dial Int; 2006; 26(3):320-7. PubMed ID: 16722024
[TBL] [Abstract][Full Text] [Related]
56. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.
Brandenburg VM; Schlieper G; Heussen N; Holzmann S; Busch B; Evenepoel P; Vanholder R; Meijers B; Meert N; Fassbender WJ; Floege J; Jahnen-Dechent W; Ketteler M
Nephrol Dial Transplant; 2010 Aug; 25(8):2672-9. PubMed ID: 20172849
[TBL] [Abstract][Full Text] [Related]
57. Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels.
Kokuho T; Toya Y; Kawaguchi Y; Tamura K; Iwatsubo K; Dobashi Y; Nakazawa A; Takeda H; Iwatsubo M; Hirawa N; Yasuda G; Ohnishi T; Umemura S
Ther Apher Dial; 2007 Dec; 11(6):442-8. PubMed ID: 18028171
[TBL] [Abstract][Full Text] [Related]
58. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients.
Wilkes BM; Reiner D; Kern M; Burke S
Clin Nephrol; 1998 Dec; 50(6):381-6. PubMed ID: 9877112
[TBL] [Abstract][Full Text] [Related]
59. Impact of dialysis on gastroesophageal reflux, dyspepsia, and proton pump inhibitor treatment in patients with chronic renal failure.
Strid H; Fjell A; Simrén M; Björnsson ES
Eur J Gastroenterol Hepatol; 2009 Feb; 21(2):137-42. PubMed ID: 19212202
[TBL] [Abstract][Full Text] [Related]
60. Clinical efficacy, safety and anti-inflammatory activity of two sevelamer tablet forms in patients on low-flux hemodialysis.
Tzanno-Martins C; Biavo BM; Ferreira-Filho O; Ribeiro-Junior E; João-Luiz MV; Degaspari S; Scavone C; Kawamoto E
Int J Immunopathol Pharmacol; 2014; 27(1):25-35. PubMed ID: 24674676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
